Lava Therapeutics NV
https://lavatherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lava Therapeutics NV
More Spanish Biotechs To Benefit From Ysios Backing
Spain now enjoys a reasonable level of venture capital to help translate its scientific excellence into budding biotechs and the country's major life sciences backer Ysios is looking to unearth more jewels there, as well as in the rest of Europe and North America.
Novo Ventures Remains Bullish After ‘Very Active’ Year
In this latest installment of VC playbook, In Vivo speaks to Naveed Siddiqi, senior partner at Novo Ventures. He discusses the group’s strategy, the European investment outlook for life sciences and how COVID-19 has permanently shifted perceptions of the biopharma industry.
IPO Update: What A Difference A (Pandemic) Year Makes
Just nine drug developers went public in the US during the first quarter of last year, but with the industry boosted by pandemic response, 32 biopharma companies launched IPOs in Q1 of this year.
Finance Watch: Two New VC Funds Raise $755m To Fund Innovation
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Lava Therapeutics BV